Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 1993

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

A clinical comparison of two triphasic oral contraceptives with

levonorgestrel or norethindrone: a prospective, randomized, single-blind

study.

AUTHORS

Masson S; Franssen E; Hilditch JR; Powell MG

SOURCE

CONTRACEPTION. 1993 Jan;47(1):43-54.

ABSTRACT

Menstrual bleeding patterns were investigated in young women taking either a levonorgestrel triphasic, Triquilar, or a

norethindrone triphasic, Ortho 7/7/7, 2 commonly prescribed low-dose oral contraceptives. The levonorgestrel

triphasic contains ethinyl estradiol (EE) 30 mcg + levonorgestrel (LNG) 50 mcg for the 1st 6 days, EE 40 mcg + LNG

75 mcg for the following 5 days, and EE 30 mcg + LNG 125 mcg for the last 10 days. The norethindrone triphasic

contains EE 35 mcg + norethindrone (NET) 0.5 mg for the 1st 7 days, EE 35 mcg + NET 0.75 mg for the following 7

days and EE 35 mcg + NET 1.0 mg for the last 7 days. 300 women from 16-25 years of age were randomized to the

levonorgestrel triphasic (n=150) or the norethindrone triphasic (n=150) groups. Assessments were made from daily

diary cards and from bimonthly investigator interviews over 6 pill cycles. The results showed a higher incidence of

intermenstrual bleeding (breakthrough bleeding and/or spotting) in the norethindrone triphasic group (NET group) than

in the levonorgestrel triphasic group (LNG group): 44.9% of patients (66/147) randomized to the LNG group reported

intermenstrual bleeding 1 or more times during the study compared with 61.9% (91/147) randomized to the NET group

(p = 0.0036). Furthermore, in subjects who did not miss any pills, the proportion of patients with intermenstrual

bleeding in each cycle was significantly greater (p<0.02, cycles 1-4, 6; p>0.05, cycle 5) and was experienced for

more days/cycle (p<0.05, cycle 1) and for more cycles/patient (p<0.05, 5 cycles) in the NET group compared with the

LNG group. Intermenstrual bleeding was also less frequently observed in the LNG group than in the NET group in

patients who missed pills (p<0.05, cycles 3, 5, and 6). In addition, early withdrawal bleeding occurred more often in

the NET group than in the LNG group (p<0.05, cycles 1, 3, and 4). The incidence of amenorrhea was similar in both

groups. These results demonstrate a significantly lower incidence of intermenstrual bleeding and therefore better

cycle control with the levonorgestrel triphasic Triquilar as compared with the norethindrone triphasic Ortho 7/7/7.

(PubHealth.info Document ID: CONT2T 4530-06)

PubHealth.info NOTE: The author(s) of this article titled, "A clinical comparison of two triphasic oral contraceptives

with levonorgestrel or norethindrone: a prospective, randomized, single-blind study.", is(are) Masson S; Franssen E;

Hilditch JR; Powell MG. The source of this article is "CONTRACEPTION. 1993 Jan;47(1):43-54.". This article was

published in 1993 in English language(s). (PubHealth.info® Document ID: CONT2T 4530-06. All rights reserved with

PubHealth.info) PIN: 9530

This article is peer-reviewed.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.